Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying

By Keith Speights – Updated Aug 17, 2021 at 4:26PM

Key Points

  • Wood's ARK Genomic Revolution ETF has reduced its stake in a big biotech with strong short-term and long-term growth prospects.
  • Her ARK Innovation ETF and ARK Next Generation Internet ETF sold shares of an innovative company with three growth platforms.
  • The ARK Next Generation Internet ETF has also been selling shares of another company poised to benefit from changes.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wood might regret trimming her positions in these great growth stocks.

One person's trash is another person's treasure. That's proven out every single day on the stock market. Every time a stock is sold by one person, there's another person on the other end of the transaction ready and willing to buy the stock.

I wouldn't say, though, that every time someone sells a stock they think it's trash. For example, well-known investor Cathie Wood recently sold shares of several companies that are still holdings in her ARK exchange-traded funds (ETFs). While she obviously had reasons to sell these stocks, it doesn't necessarily mean that she thinks poorly of them.

There are some stocks in which the ARK ETFs reduced their positions that still have strong growth prospects. Here are three growth stocks that Wood is selling that I think are especially still worth buying.

A die with "buy" on one side and "sell" on another side.

Image source: Getty Images.

Regeneron Pharmaceuticals

Wood's ARK Genomic Revolution ETF has sold shares of Regeneron Pharmaceuticals (REGN 0.12%) six times so far in August. However, the biotech stock still remains one of the top 10 holdings for the ETF.

I think Regeneron's short- and long-term prospects continue to be very good. Over the short term, the latest COVID-19 wave should boost sales of the company's REGEN-COV COVID-19 antibody cocktail. But it's Regeneron's long-term opportunities that provide the main reason to consider buying the stock.

Eye-disease drug Eylea and autoimmune disease drug Dupixent continue to enjoy solid momentum. Regeneron is evaluating both drugs in phase 3 clinical studies with the hopes of picking up additional approved indications.

Libtayo could be the company's next blockbuster. That's especially the case after a late-stage study of the drug in combination with chemotherapy was recently stopped early because the combo was so effective in improving survival in patients with advanced non-small cell lung cancer.

I also like Regeneron's pipeline. It's loaded with experimental antibody therapies targeting a wide range of diseases. In addition, the company has a fast-growing cash stockpile that it could use to further bolster its pipeline.

Sea Limited

Two of Wood's ETFs have trimmed their positions in Sea Limited (SE -2.35%) this month -- her flagship ARK Innovation ETF and the ARK Next Generation Internet ETF. Both ETFs still own sizable stakes in Sea Limited, though.

I agree with my Motley Fool colleagues Brian Feroldi and Brian Stoffel that even after huge gains over the last two years, Sea Limited is just getting started. For example, the company plans to develop its extraordinarily popular Free Fire mobile game into a full-blown social platform.

Free Fire is gaining momentum not only in Southeast Asia and Latin America, but also in other parts of the world. Sea Limited is expanding its gaming ecosystem with esports and collaborations with third-party developers as well.

But it's a mistake to view Sea Limited as only a gaming play. The company also has an up-and-coming e-commerce platform with Shopee and a digital financial services business built around SeaMoney. My take is that both of these businesses will generate strong growth over the long run.

The Trade Desk

The ARK Next Generation Internet ETF has also sold more than 800,000 shares of The Trade Desk (TTD -0.30%) so far in August. Even with those sales, however, the stock still ranks in the top 25 holdings for the ETF.

There are similarities between my views of Regeneron and The Trade Desk, although their businesses are about as different as you can get. Both companies have strong short-term and long-term prospects.

One key short-term growth driver for The Trade Desk is its recent launch of the Solimar digital advertising platform. It's the company's biggest release ever. CEO Jeff Green said in the second-quarter conference call that management expects the majority of impressions on its overall platform will be purchased using Solimar by the beginning of 2022.

I also think that The Trade Desk is like Sea Limited in that they're both just getting started. Independent research firm MoffettNathanson expects that the ad-supported video-on-demand market will reach nearly $18 billion by 2025. That's four times larger than the market size last year. The Trade Desk is poised to benefit significantly from this growth. 

Keith Speights owns shares of Sea Limited and The Trade Desk. The Motley Fool owns shares of and recommends Sea Limited and The Trade Desk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.